CFDE Data Portal | Search DOP1B

	Label	Description
	DOP1B Gene (Entity type)	ENSG00000142197 - DOP1 leucine zipper like protein B
	GSE216273,GSE216292 14 V 6 PALBOCICLIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE150244 TRIM8 knockout 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE131887 5 V 2 DOXYCYCLINE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE228727 2 V 1 DAPAGLIFLOZIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE199107 tryptophan 6 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE168401 2 V 0 HARMINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

DOP1B

ENSG00000142197 - DOP1 leucine zipper like protein B

GSE216273,GSE216292 14 V 6 PALBOCICLIB HUMAN DN

A Gene Set from LINCS

GSE150244 TRIM8 knockout 3 v 0 human dn

A Gene Set from LINCS

GSE131887 5 V 2 DOXYCYCLINE MOUSE UP

A Gene Set from LINCS

GSE228727 2 V 1 DAPAGLIFLOZIN MOUSE UP

A Gene Set from LINCS

GSE138789 metformin 0 v 1 human up

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 6 v 11 human up

A Gene Set from LINCS

GSE199107 tryptophan 6 v 7 human up

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up

A Gene Set from LINCS

GSE168401 2 V 0 HARMINE HUMAN DN

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.